European Companies Search Engine
UK funding (£1,426,708): siRNA therapy in dominant skin and eye disorders Ukri18 Feb 2010 UK Research and Innovation, United Kingdom
Overview
Text
siRNA therapy in dominant skin and eye disorders
| Abstract | Incurable genetic diseases represent a major cost to the NHS, requiring specialist care costing billions per annum. RNA interference is a new Nobel prize winning technology that is suitable for treatment of a large number of genetic disorders but a major hurdle to applying this clinically is the the problem of delivery of these therapy molecules, that are slightly larger than conventional drugs, into the target tissues and organs. This programme grant focuses on a group of painful, debilitating genetic skin diseases and a related corneal eye disease, where the target tissues are very small and very accessible. The programme brings together leading researchers who uncovered the genes causing these disorders, with experts in developing new methods to deliver molecules into skin or cornea. State-of-the-art model systems will be developed to validate delivery of these new formulations into the skin and the cornea, setting the scene for taking this new therapy method into the clinic. |
| Category | Research Grant |
| Reference | G0802780/1 |
| Status | Closed |
| Funded period start | 18/02/2010 |
| Funded period end | 17/02/2015 |
| Funded value | £1,426,708.00 |
| Source | https://gtr.ukri.org/projects?ref=G0802780%2F1 |
Participating Organisations
| University of Dundee |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: University of Dundee, Dundee.
The visualizations for "University of Dundee - UK funding (£1,426,708): siRNA therapy in dominant skin and eye disorders"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
